These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12529875)

  • 1. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
    Hudgens MG
    Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.
    Song JX
    Pharm Stat; 2006; 5(4):295-304. PubMed ID: 17128429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudo-likelihood methods for longitudinal binary data with non-ignorable missing responses and covariates.
    Parzen M; Lipsitz SR; Fitzmaurice GM; Ibrahim JG; Troxel A
    Stat Med; 2006 Aug; 25(16):2784-96. PubMed ID: 16345018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The quest for an HIV vaccine].
    Girard MP
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary.
    Gorse GJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S141-3. PubMed ID: 7865289
    [No Abstract]   [Full Text] [Related]  

  • 12. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
    Liu A; Wu C; Yu KF; Gehan E
    Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
    Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Starting from scratch: program development and lessons learned from HIV vaccine trial counseling in Thailand.
    Thapinta D; Jenkins RA
    Contemp Clin Trials; 2007 Jul; 28(4):409-22. PubMed ID: 17196444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response".
    Jamieson BD; Ibarrondo FJ; Wong JT; Hausner MA; Ng HL; Fuerst M; Price C; Shih R; Elliott J; Hultin PM; Hultin LE; Anton PA; Yang OO
    Vaccine; 2006 Apr; 24(17):3426-31. PubMed ID: 16545508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.